Anwaar Saeed, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    AstraZeneca, Bristol-Myers Squibb, Merck, Exelixis, Pfizer, Xilio therapeutics, Taiho, Amgen, Autem therapeutics, Arcus therapeutics, KAHR medical, and Daiichi Sankyo
    Topic:
    therapeutic applications in GI malignancies
    Date added:
    08/26/2024
    Date updated:
    08/26/2024
  • Attribution:
    Other
    Type of financial relationship:
    Contracted Research
    Ineligible company:
    AstraZeneca, Bristol-Myers Squibb, Merck, Clovis, Exelixis, Actuate therapeutics, Incyte Corporation, Daiichi Sankyo, Five prime therapeutics, Amgen, Innovent biologics, Dragonfly therapeutics, Oxford Biotherapeutics, Arcus therapeutics, and KAHR medical
    Topic:
    Therapeutic applications in GI malignancies
    Date added:
    08/26/2024
    Date updated:
    08/26/2024
Return to Sept. 27-28, 2024 - Symposium for Evolving Therapies and Drug Development in Oncology